ArticleCell discovery2025
ShennongAlpha: an AI-driven sharing and collaboration platform for intelligent curation, acquisition, and translation of natural medicinal material knowledge.
Article in Cell discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Rethinking Nature's Pharmacy: AI Era and Natural Product Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Development and application of artificial intelligence in traditional Chinese medicine research and development.Chinese medicine · 2026Review
- XuanHuGPT: parameter-efficient fine-tuning of large language model in the field of traditional Chinese medicine.Chinese medicine · 2025Article
- A Review on the Applications of Artificial Intelligence for Diagnosing and Treating Cervical Cancer.International journal of women's health · 2025Review
- Exploring the potential of large language model-based chatbots in challenges of ribosome profiling data analysis: a review.Briefings in bioinformatics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural Medicinal Materials (NMMs) have a long history of global clinical applications and a wealth of records and knowledge. Although NMMs are a major source for drug discovery and clinical application, the utilization and sharing of NMM knowledge face crucial challenges, including the standardized description of critical information, efficient curation and acquisition, and language barriers. To address these, we developed ShennongAlpha, an artificial intelligence (AI)-driven sharing and collaboration platform for intelligent knowledge curation, acquisition, and translation. For standardized knowledge curation, the platform introduced a Systematic Nomenclature to enable accurate differentiation and identification of NMMs. More than fourteen thousand Chinese NMMs have been curated into the platform along with their knowledge. Furthermore, the platform pioneered chat-based knowledge acquisition, standardized machine translation, and collaborative knowledge updating. Together, our study represents the first major advance in leveraging AI to empower NMM knowledge sharing, which not only marks a novel application of AI for science, but also will significantly benefit the global biomedical, pharmaceutical, physician, and patient communities.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.